Alexion and The Community Foundation for Greater New Haven Launch Here in New Haven

30-Day Grant Program Supporting Local Non-Profit Organizations

Congratulations to the grant recipients:

Week I: Columbus House, Arte Inc, Abilities Without Boundaries, Boy Scouts of America, Christian Community Action
Week II: CT Food Bank, Music Haven, Clifford Beers Clinic, Solar Youth
Week III: AIDS Project New Haven, New Reach, ConnCAT, Fair Haven Community Health Center, Girl Scouts of Connecticut
Week IV: JUNTA for Progressive Action, Community Soup Kitchen, Neighborhood Music School, Chapel Haven, New Haven Reads
Week V: New Haven Farms, Liberty Community Services, Shubert Theatre (CAPA), Project Access-New Haven, Boys & Girls Club of New Haven
Week VI: New Haven Land Trust, Downtown Evening Soup Kitchen, Arts Council of Greater New Haven, Easter Seals Goodwill Industries, Youth Continuum
February 29: Integrated Refugee & Immigrant Services (IRIS)

NEW HAVEN, Conn.—January 19, 2016—Alexion Pharmaceuticals, Inc. and The Community Foundation for Greater New Haven announced today the launch of Here in New Haven, a charitable giving initiative to support 30 local non-profit organizations dedicated to strengthening the greater New Haven community. The program, which coincides with Alexion's move to its new global headquarters at 100 College Street, is part of the Company's commitment to developing productive partnerships within the communities where employees live and work. Through this initiative, Alexion will provide a $1,000 grant each day over a period of 30 business days, culminating on February 29, 2016, which is Global Rare Disease Day.

"Alexion was founded 24 years ago in New Haven, and we are pleased to be back here establishing our global headquarters with a commitment to supporting vital economic, social and environmental efforts in our community," said David Hallal, Chief Executive Officer of Alexion. "Our partnership with The Community Foundation for Greater New Haven will support 30 organizations dedicated to creating positive change through charitable resources that address priorities in the region."

"We are thrilled to partner with Alexion on this initiative, which utilizes® to recognize and support the many deserving organizations serving New Haven that help our community continue to grow and thrive," said William W. Ginsberg, President and CEO, The Community Foundation for Greater New Haven. "We are equally thrilled that Alexion is returning to New Haven and appreciate the commitment of the company and its employees to our community."

Today's grant recipient is Columbus House, whose mission is to serve people who are homeless or at risk of becoming homeless by providing shelter and housing and by fostering their personal growth and independence. Grantees will be announced daily on's Facebook page and Twitter feed.

Recipients of the Here in New Haven grants were selected from a list of New Haven-serving non-profits profiled on®, an online resource for learning and giving provided by The Community Foundation. Each organization will be invited to the opening of the new Alexion global headquarters, which will include a building dedication and remarks from both Alexion and Connecticut state and local officials.

A full list of grant recipients will be available at on February 29.

About Alexion
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal
hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional
severe and ultra-rare disorders. Alexion's metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas.
Further information about Alexion can be found at:

About The Community Foundation for Greater New Haven
Thanks to the generosity of three generations of donors, The Community Foundation for Greater New Haven awarded over $30 million in grants and distributions in 2015 from charitable assets of more than $500 million and composed of hundreds of individually named funds. In addition to its grantmaking, The Community Foundation helps build a stronger community by taking measures to improve student achievement, create healthy families in New Haven, promote local philanthropy through® and The Great Give®, and encourage better understanding of the region. The Community Foundation for Greater New Haven's 20 town service area includes: Ansonia, Bethany, Branford, Cheshire, Derby, East Haven, Guilford, Hamden, Madison, Milford, New Haven, North Branford, North Haven, Orange, Oxford, Seymour, Shelton, Wallingford, West Haven and Woodbridge. For more
information, visit or follow The Foundation on Facebook ( and
Twitter (

Alexion Pharmaceuticals, Inc.
Stephanie Fagan, 203-271-8223
Senior Vice President, Corporate Communications
Kim Diamond, 203-439-9600
Executive Director, Corporate Communications
The Community Foundation for Greater New Haven
Tricia Caldwell, 203-777-7090
Director of Communications